Strativa

Strativa Pharmaceuticals was the branded specialty division of Par Pharmaceutical Companies, Inc., focusing on the commercialization of proprietary products in the oncology and supportive care markets. The company's portfolio featured Zuplenz (ondansetron) oral soluble film for nausea and Oravig (miconazole) buccal tablets for oral candidiasis. Strativa also maintained a significant co-promotion agreement with Cephalon for the wakefulness-promoting agent Nuvigil. In 2015, its parent company, Par Pharmaceutical, was acquired by Endo International for approximately $8.05 billion, leading to the integration of Strativa's assets into Endo's specialty pharmaceutical business.